$TVGN
Tevogen Bio Holdings Inc. Stock $tvgn

$tvgn Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224032294 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue			$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin			$526.6K
YoY Change			103.64%
% of Gross Profit
Research & Development	$3.261M	$4.124M	$2.379M
YoY Change	191.96%	73.4%
% of Gross Profit
Depreciation & Amortization			$79.50K
YoY Change			143.12%
% of Gross Profit
Operating Expenses	$6.086M	$8.599M	$526.6K
YoY Change	897.63%	1533.0%	103.64%
Operating Profit	-$6.086M	-$8.599M	-$2.184M
YoY Change	161.74%	293.64%
Interest Expense	$12.46K		$331.5K
YoY Change	-96.22%		140.67%
% of Operating Profit
Other Income/Expense, Net			$331.5K
YoY Change			-28.79%
Pretax Income			-$195.1K
YoY Change			-194.23%
Income Tax
% Of Pretax Income
Net Earnings	-$5.884M	-$9.663M	-$195.1K
YoY Change	2010.96%	4854.19%	-194.23%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.03	-$0.04	-$0.18
Diluted Earnings Per Share	-$0.03	-$0.04	-$0.01
COMMON SHARES
Basic Shares Outstanding	170.6M shares	164.6M shares	120.0M shares
Diluted Shares Outstanding	170.2M shares	154.2M shares	120.0M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments			$556.0K
YoY Change			199.49%
Cash & Equivalents	$2.331M	$1.135M	$25.00M
Short-Term Investments
Other Short-Term Assets			$143.3K
YoY Change			-64.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$3.528M	$2.447M	$699.3K
YoY Change	783.09%	249.87%	17.58%
LONG-TERM ASSETS
Property, Plant & Equipment	$337.0K	$377.5K	$1.123M
YoY Change	-67.25%	-66.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$133.3K	$133.3K	$25.68M
YoY Change	-99.49%	-99.48%	-92.71%
Total Long-Term Assets	$761.8K	$863.5K	$25.68M
YoY Change	-97.07%	-96.64%	-92.71%
TOTAL ASSETS
Total Short-Term Assets	$3.528M	$2.447M	$699.3K
Total Long-Term Assets	$761.8K	$863.5K	$25.68M
Total Assets	$4.289M	$3.310M	$26.38M
YoY Change	-83.76%	-87.45%	-92.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.838M	$6.666M	$694.9K
YoY Change	483.84%	859.28%	287.73%
Accrued Expenses	$1.405M	$1.776M	$882.0K
YoY Change	-31.68%	101.37%
Deferred Revenue
YoY Change
Short-Term Debt			$625.7K
YoY Change
Long-Term Debt Due			$62.93M
YoY Change
Total Short-Term Liabilities	$10.42M	$10.61M	$1.521M
YoY Change	470.18%	597.87%	486.58%
LONG-TERM LIABILITIES
Long-Term Debt			$0.00
YoY Change
Other Long-Term Liabilities			$14.73M
YoY Change			-0.93%
Total Long-Term Liabilities			$14.73M
YoY Change			-0.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.42M	$10.61M	$1.521M
Total Long-Term Liabilities			$14.73M
Total Liabilities	$10.48M	$10.94M	$16.25M
YoY Change	-36.73%	-32.65%	7.43%
SHAREHOLDERS EQUITY
Retained Earnings	-$103.9M	-$98.06M	-$15.55M
YoY Change	543.0%	530.52%	10.7%
Common Stock	$17.08K	$16.88K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.190M	-$7.634M	-$15.55M
YoY Change
Total Liabilities & Shareholders Equity	$4.289M	$3.310M	$26.38M
YoY Change	-83.76%	-87.45%	-92.53%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$5.884M	-$9.663M	-$195.1K
YoY Change	2010.96%	4854.19%	-194.23%
Depreciation, Depletion And Amortization			$79.50K
YoY Change			143.12%
Cash From Operating Activities			-$397.3K
YoY Change			765.53%
INVESTING ACTIVITIES
Capital Expenditures			$133.0K
YoY Change			-28.88%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities			$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities			901.0K
YoY Change			-81.98%
NET CHANGE
Cash From Operating Activities			-397.3K
Cash From Investing Activities			0.000
Cash From Financing Activities			901.0K
Net Change In Cash			503.7K
YoY Change			-1197.43%
FREE CASH FLOW
Cash From Operating Activities			-$397.3K
Capital Expenditures			$133.0K
Free Cash Flow			-$530.3K
YoY Change			127.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001860871
	dei	Document Type DocumentType	10-Q
CY2024Q2	us-gaap	Assets Assets	3310259	usd
	us-gaap	Net Income Loss NetIncomeLoss	-52940497	usd
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	170646864	shares
CY2024Q2	us-gaap	Cash Cash	1135390	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1152554	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	2446763	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	377547	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	352673	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	133276	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	6666229	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1776047	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	268672	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	10611948	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	96809	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4508748	usd
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q2	us-gaap	Deferred Costs DeferredCosts		usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2024Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2024Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2023Q4	TVGN	Written Call Option Derivative Liabilities Noncurrent WrittenCallOptionDerivativeLiabilitiesNoncurrent		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts		usd
CY2023Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts		usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts		usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2024Q2	TVGN	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes		usd
CY2023Q2	TVGN	Change In Fair Value Of Written Call Option Derivative Liabilities ChangeInFairValueOfWrittenCallOptionDerivativeLiabilities		usd
	TVGN	Change In Fair Value Of Written Call Option Derivative Liabilities ChangeInFairValueOfWrittenCallOptionDerivativeLiabilities		usd
CY2023Q2	TVGN	Loss On Issuance Of Commitment Shares LossOnIssuanceOfCommitmentShares		usd
	TVGN	Loss On Issuance Of Commitment Shares LossOnIssuanceOfCommitmentShares		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther		usd
CY2024Q2	TVGN	Stock Issued During Period Value Settlement Of Vested Restricted Stock Units StockIssuedDuringPeriodValueSettlementOfVestedRestrictedStockUnits		usd
CY2024Q2	TVGN	Stock Issued During Period Value Contribution From Related Party StockIssuedDuringPeriodValueContributionFromRelatedParty		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts		usd
	TVGN	Loss On Preferred Stock Issuance LossOnPreferredStockIssuance		usd
	TVGN	Loss On Issuance Of Commitment Shares LossOnIssuanceOfCommitmentShares		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	TVGN	Issuance Of Written Call Option IssuanceOfWrittenCallOption		usd
	TVGN	Change In Fair Value Of Written Call Option Derivative Liabilitie ChangeInFairValueOfWrittenCallOptionDerivativeLiabilitie		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	TVGN	Cash Acquired In Connection With Reverse Recapitalization CashAcquiredInConnectionWithReverseRecapitalization		usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
	TVGN	Nonrefundable Prepaid Proceeds Towards Anticipated Preferred Stock Issuance NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	TVGN	Despac Transaction Fees Included In Accrued Expenses And Other Liabilities DespacTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities		usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1		usd
	TVGN	Repurchase Of Series B Preferred Stock RepurchaseOfSeriesBPreferredStock		usd
	us-gaap	Stock Issued1 StockIssued1		usd
CY2023Q2	TVGN	Cumulative Undeclared Series Dividends CumulativeUndeclaredSeriesDividends		usd
	TVGN	Cumulative Undeclared Series Dividends CumulativeUndeclaredSeriesDividends		usd
CY2023Q2	TVGN	Preferred Stock Repurchased Basic PreferredStockRepurchasedBasic		usd
	TVGN	Preferred Stock Repurchased Basic PreferredStockRepurchasedBasic		usd
CY2024Q2	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic		usd
CY2023Q2	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic		usd
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic		usd
CY2023Q2	TVGN	Cumulative Undeclared Series Dividends Diluted CumulativeUndeclaredSeriesDividendsDiluted		usd
	TVGN	Cumulative Undeclared Series Dividends Diluted CumulativeUndeclaredSeriesDividendsDiluted		usd
CY2023Q2	TVGN	Preferred Stock Repurchased Diluted PreferredStockRepurchasedDiluted		usd
	TVGN	Preferred Stock Repurchased Diluted PreferredStockRepurchasedDiluted		usd
CY2024Q2	TVGN	Convertible Promissory Note Interest Diluted ConvertiblePromissoryNoteInterestDiluted		usd
CY2023Q2	TVGN	Convertible Promissory Note Interest Diluted ConvertiblePromissoryNoteInterestDiluted		usd
	TVGN	Convertible Promissory Note Interest Diluted ConvertiblePromissoryNoteInterestDiluted		usd
CY2024Q2	TVGN	Convertible Promissory Note Change In Fair Value Diluted ConvertiblePromissoryNoteChangeInFairValueDiluted		usd
CY2023Q2	TVGN	Convertible Promissory Note Change In Fair Value Diluted ConvertiblePromissoryNoteChangeInFairValueDiluted		usd
	TVGN	Convertible Promissory Note Change In Fair Value Diluted ConvertiblePromissoryNoteChangeInFairValueDiluted		usd
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities		shares
CY2024Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41002
	dei	Entity Registrant Name EntityRegistrantName	Tevogen Bio Holdings Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1597194
	dei	Entity Address Address Line1 EntityAddressAddressLine1	15 Independence Boulevard
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite #410
	dei	Entity Address City Or Town EntityAddressCityOrTown	Warren
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07059
	dei	City Area Code CityAreaCode	(877)
	dei	Local Phone Number LocalPhoneNumber	838-6436
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.0001
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	2582870	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	1651000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	80712000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85479542	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	14220000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	234858	usd
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	22185	usd
CY2024Q2	TVGN	Written Call Option Derivative Liabilities Noncurrent WrittenCallOptionDerivativeLiabilitiesNoncurrent	213214	usd
CY2024Q2	us-gaap	Liabilities Liabilities	10944156	usd
CY2023Q4	us-gaap	Liabilities Liabilities	99934400	usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	2799990	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	168826402	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	168826402	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	119999989	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	119999989	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	16883	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	12000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	87605572	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	5216840	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98056342	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-99657737	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-7633897	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-94428897	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3310259	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5505503	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4124450	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1031393	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24936032	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2378566	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4474577	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1153073	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13179719	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2130182	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	8599027	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2184466	usd
	us-gaap	Operating Expenses OperatingExpenses	38115751	usd
	us-gaap	Operating Expenses OperatingExpenses	4508748	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8599027	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2184466	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-38115751	usd
CY2024Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	6	usd
CY2023Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-299887	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-155780	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-588884	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	7499353	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-38788	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6815	usd
CY2023Q2	TVGN	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-19700000	usd
	TVGN	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	48468678	usd
	TVGN	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-47842865	usd
CY2024Q2	TVGN	Change In Fair Value Of Written Call Option Derivative Liabilities ChangeInFairValueOfWrittenCallOptionDerivativeLiabilities	213214	usd
	TVGN	Change In Fair Value Of Written Call Option Derivative Liabilities ChangeInFairValueOfWrittenCallOptionDerivativeLiabilities	213214	usd
CY2024Q2	TVGN	Loss On Issuance Of Commitment Shares LossOnIssuanceOfCommitmentShares	890000	usd
	TVGN	Loss On Issuance Of Commitment Shares LossOnIssuanceOfCommitmentShares	890000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-9663447	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-22184353	usd
	us-gaap	Net Income Loss NetIncomeLoss	1601395	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6075379	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22184353	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5044907	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-52940497	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6075379	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-22184353	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-43124798	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-52940497	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	154167090	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	119999989	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145655205	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	119999989	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	154167090	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	119999989	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148154361	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	119999989	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-94428897	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2799990	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	200000	usd
CY2024Q1	TVGN	Stock Issued During Period Value New Issues One StockIssuedDuringPeriodValueNewIssuesOne	3613000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	46622627	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2883981	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	676500	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26333249	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	11264842	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-5802670	usd
CY2024Q2	TVGN	Stock Issued During Period Value Commitment Shares In Connection With Unsecured Equity Line Of Credit Facility StockIssuedDuringPeriodValueCommitmentSharesInConnectionWithUnsecuredEquityLineOfCreditFacility	890000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	2800000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4142220	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-9663447	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-7633897	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-33951217	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30756144	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-64707361	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-64707361	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-22184353	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-22184353	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-86891714	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-86891714	usd
	us-gaap	Net Income Loss NetIncomeLoss	1601395	usd
	us-gaap	Net Income Loss NetIncomeLoss	-52940497	usd
	us-gaap	Depreciation Depreciation	81104	usd
	us-gaap	Depreciation Depreciation	79471	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	30475469	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	159305	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	589135	usd
	us-gaap	Noncash Merger Related Costs NoncashMergerRelatedCosts	7099353	usd
	TVGN	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	48468678	usd
	TVGN	Change In Fair Value Of Convertible Promissory Notes ChangeInFairValueOfConvertiblePromissoryNotes	-47842865	usd
	TVGN	Loss On Preferred Stock Issuance LossOnPreferredStockIssuance	799990	usd
	TVGN	Loss On Issuance Of Commitment Shares LossOnIssuanceOfCommitmentShares	890000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-6815	usd
	TVGN	Issuance Of Written Call Option IssuanceOfWrittenCallOption	375000	usd
	TVGN	Change In Fair Value Of Written Call Option Derivative Liabilitie ChangeInFairValueOfWrittenCallOptionDerivativeLiabilitie	-161786	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	117189	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	104438	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	479471	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-144472	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	68446	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-21343	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	3151676	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	372614	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-589529	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-500656	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-122091	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-107839	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5146335	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4394654	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	133000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-133000	usd
	TVGN	Cash Acquired In Connection With Reverse Recapitalization CashAcquiredInConnectionWithReverseRecapitalization	229328	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	2000000	usd
	TVGN	Nonrefundable Prepaid Proceeds Towards Anticipated Preferred Stock Issuance NonrefundablePrepaidProceedsTowardsAnticipatedPreferredStockIssuance	3000000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2500000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5229328	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2500000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	82993	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2027654	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1052397	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5484265	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1135390	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3456611	usd
	TVGN	Despac Transaction Fees Included In Accrued Expenses And Other Liabilities DespacTransactionFeesIncludedInAccruedExpensesAndOtherLiabilities	276000	usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	46622627	usd
	TVGN	Repurchase Of Series B Preferred Stock RepurchaseOfSeriesBPreferredStock	3613000	usd
	us-gaap	Stock Issued1 StockIssued1	3113309	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-98056342	usd
CY2024Q2	us-gaap	Cash Cash	1135390	usd
	TVGN	Drawing Down Term Loans DrawingDownTermLoans	1000000	usd
	TVGN	Drawing Down Term Loans Net DrawingDownTermLoansNet	36000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84F_eus-gaap--UseOfEstimates_zeSwUwmqs8f4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_z23bDAansePa">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing unaudited consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of expenses. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the unaudited consolidated financial statements in the period they are determined to be necessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant areas that require management’s estimates include the fair value of the common stock and convertible promissory notes prior to the Merger, the fair value of the Series A Preferred Stock and Series B Preferred Stock, fair value of the purchase options under the Loan Agreement, stock-based compensation assumptions, the estimated useful lives of property and equipment and accrued research and development expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zSY2x9IJ02Gl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zaDG4Yhydou">Concentrations of Credit Risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	TVGN	Free Standing Purchase Options FreeStandingPurchaseOptions	14000000	shares
	TVGN	Embedded Options EmbeddedOptions	36000000	shares
CY2024Q2	us-gaap	Share Price SharePrice	10.00
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	164614418	shares
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	229328	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	158819	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Prepaid Expense And Other Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets	2501	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	96175	usd
CY2024Q1	TVGN	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accrued Expenses BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedExpenses	1269126	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Long Term Debt BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt	1651000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther	29000	usd
CY2024Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	-2654653	usd
CY2024Q1	TVGN	Merger Transaction Costs Limited To Cash Acquired MergerTransactionCostsLimitedToCashAcquired	-229328	usd
CY2024Q1	TVGN	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net Plus Transaction Costs BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetPlusTransactionCosts	-2883981	usd
CY2024Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	7728681	usd
CY2024Q1	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	229328	usd
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	7499353	usd
CY2024Q1	TVGN	Stock Issued During Period Value New Issues One StockIssuedDuringPeriodValueNewIssuesOne	3613000	usd
CY2024Q2	TVGN	Accrued Professional Service Fees Current AccruedProfessionalServiceFeesCurrent	1387446	usd
CY2023Q4	TVGN	Accrued Professional Service Fees Current AccruedProfessionalServiceFeesCurrent	976301	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	388601	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	120149	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1776047	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1096450	usd
	TVGN	Loss On Issuance Of Commitment LossOnIssuanceOfCommitment	890000	usd
	TVGN	Lender Issuance Date Fair Value LenderIssuanceDateFairValue	105000	usd
	TVGN	Additional Issuance Date Fair Value AdditionalIssuanceDateFairValue	270000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4142220	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30475469	usd
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	usd
CY2023Q2	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0	usd
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	168826402	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	168826402	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	168826402	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	168826402	shares
CY2024Q2	TVGN	Vested Performancebased Restricted Stock Units From Satisfaction Of Liquidity Condition Upon Closing VestedPerformancebasedRestrictedStockUnitsFromSatisfactionOfLiquidityConditionUponClosing	5462378	shares
CY2024Q2	TVGN	Shares Subject To Future Vesting Issuance Of Restricted Common Stock Subject To Forfeiture SharesSubjectToFutureVestingIssuanceOfRestrictedCommonStockSubjectToForfeiture	-19348954	shares
CY2024Q2	TVGN	Common Stock Shares Issued And Outstanding Inclusion Of Shares To Be Issued And Exclusion Of Shares Subject To Forfeiture CommonStockSharesIssuedAndOutstandingInclusionOfSharesToBeIssuedAndExclusionOfSharesSubjectToForfeiture	154939826	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
	us-gaap	Sponsor Fees SponsorFees	2000000	usd
CY2024Q2	TVGN	Sponsor Fees Payable SponsorFeesPayable	250000	usd
	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	800396	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-9663447	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-22184353	usd
	us-gaap	Net Income Loss NetIncomeLoss	1601395	usd
	us-gaap	Net Income Loss NetIncomeLoss	-52940497	usd
CY2024Q2	TVGN	Cumulative Undeclared Series Dividends CumulativeUndeclaredSeriesDividends	24932	usd
	TVGN	Cumulative Undeclared Series Dividends CumulativeUndeclaredSeriesDividends	26301	usd
CY2024Q2	TVGN	Preferred Stock Repurchased Basic PreferredStockRepurchasedBasic	3613000	usd
	TVGN	Preferred Stock Repurchased Basic PreferredStockRepurchasedBasic	3613000	usd
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Basic UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic	143187	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6075379	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22184353	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	5044907	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-52940497	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-9663447	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-22184353	usd
	us-gaap	Net Income Loss NetIncomeLoss	1601395	usd
	us-gaap	Net Income Loss NetIncomeLoss	-52940497	usd
CY2024Q2	TVGN	Cumulative Undeclared Series Dividends Diluted CumulativeUndeclaredSeriesDividendsDiluted	24932	usd
	TVGN	Cumulative Undeclared Series Dividends Diluted CumulativeUndeclaredSeriesDividendsDiluted	26301	usd
CY2024Q2	TVGN	Preferred Stock Repurchased Diluted PreferredStockRepurchasedDiluted	3613000	usd
	TVGN	Preferred Stock Repurchased Diluted PreferredStockRepurchasedDiluted	3613000	usd
	TVGN	Convertible Promissory Note Interest Diluted ConvertiblePromissoryNoteInterestDiluted	155786	usd
	TVGN	Convertible Promissory Note Change In Fair Value Diluted ConvertiblePromissoryNoteChangeInFairValueDiluted	-48468678	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6075379	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-22184353	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-43124798	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-52940497	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	154167090	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	119999989	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145655205	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	119999989	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.44
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	154167090	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	119999989	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	145655205	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	119999989	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2499156	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2499156	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	154167090	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	119999989	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	148154361	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	119999989	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.44
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	65549698	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11904977	shares
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-032294-index-headers.html	Edgar Link	pending
0001493152-24-032294-index.html	Edgar Link	pending
0001493152-24-032294.txt	Edgar Link	pending
0001493152-24-032294-xbrl.zip	Edgar Link	pending
ex3-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tvgn-20240630.xsd	Edgar Link	pending
tvgn-20240630_cal.xml	Edgar Link	unprocessable
tvgn-20240630_def.xml	Edgar Link	unprocessable
tvgn-20240630_lab.xml	Edgar Link	unprocessable
tvgn-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVGN
Tevogen Bio Holdings Inc. Stock $tvgn

2024 Q3 Form 10-Q Financial Statement

#000149315224032294 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVGN Tevogen Bio Holdings Inc. Stock $tvgn

2024 Q3 Form 10-Q Financial Statement

#000149315224032294 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVGN
Tevogen Bio Holdings Inc. Stock $tvgn